ImmunoPrecise Antibodies P/E Ratio

ImmunoPrecise Antibodies (IPA) currently reports a P/E ratio of -4.1. That is below the Healthcare sector average of 22.57. Use the charts on this page to explore ImmunoPrecise Antibodies's P/E ratio history and peer comparisons.

ImmunoPrecise Antibodies's P/E ratio of -4.1 is lower than the Healthcare sector average of 22.57. That is roughly 118.2% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates ImmunoPrecise Antibodies's market price to a fundamental measure such as earnings, sales, or book value. At -4.1, IPA can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of -4.1, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.57. From there, open related valuation or income-statement pages for ImmunoPrecise Antibodies, and consider following IPA for alerts when major investors trade the stock.

ImmunoPrecise Antibodies is classified in the Healthcare sector. On P/E ratio, it currently shows -4.1 versus a sector average near 22.57. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IPA with unrelated industries.